Therapy options for COVID-19 from the rheumatologist angleAuthor(s): Paasikivi V
The clinical progression of the severe acute respiratory pattern coronavirus- 2 (SARS- CoV- 2) to critical illness is associated with a systemic and unbridled seditious response of the ingrain and adaptive impunity with the release of a plethora of proinflammatory cytokines nominated “cytokine storm”. In the absence of an effective treatment, numerous off- marker agents from the armamentarium of rheumatology are used. Then, from the perspective of a rheumatologist, we will bandy the current remedial strategies in critically ill cases with SARS- CoV- 2 pneumonia. Therefore, we will bandy the agents that aim to target viral entry and its replication into the host cell and those fastening and targeting the seditious response. In this setting, numerous agents have been used with promising results but, not all have been approved by the International Authorities and Institutions. In the first step( viral entry), SARS- CoV- 2 monoclonal antibodies and remdesivir have been approved to be used and, in the alternate step, corticosteroids along with interleukin- 6 impediments, or Janus Kinase impediments are presently used.